Xynomic Pharmaceuticals
Manufacturing · China · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1010 Middle Huaihai Rd Ste 3306, Shangha...Phone Number
+86 2154180212Website
www.xynomicpharma.comRevenue
$5.3 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Xynomic Pharmaceuticals
Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage biopharmaceutical company specializing in best-in-class oncology therapeutics. The company focuses on in-licensing, developing, and commercializing oncology drug candidates in China, the US, and globally. Their target clients include healthcare providers and patients in need of innovative cancer treatments. Xynomic Pharma is committed to advancing cancer care through its robust pipeline of drug candidates.Explore more
Xynomic Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Xynomic Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Xynomic Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Xynomic Pharmaceuticals has new funding data
Xynomic Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Xynomic Pharmaceuticals had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Xynomic Pharmaceuticals
Product Launch: Get notified when Xynomic Pharmaceuticals launches new products
Earning: See what the market has to say on Xynomic Pharmaceuticals recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check out if Xynomic Pharmaceuticals is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Xynomic Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Xynomic Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Xynomic Pharmaceuticals.
Xynomic Pharmaceuticals Tech Stack
A closer look at the technologies used by Xynomic Pharmaceuticals
See more technologies
Most Recent Scoops
Project
, according to a high-level source in Finance & Accounting, is planning to begin initiatives related to workforce management within the next six months.
Accounting, Workforce Management, Financial Reporting, Finance, HR Operations
Project
, according to a high-level source in Finance & Accounting, is planning to begin initiatives related to workforce planning within the next six months.
Accounting, Employee Relations, Workforce Management, Financial Reporting, Finance, HR Operations
Project
, according to a high-level source in Finance & Accounting, is planning to begin initiatives related to artificial intelligence and machine learning within the next six months.
Accounting, Machine Learning, Financial Reporting, Artificial Intelligence, Finance
Project
, according to a high-level source in Finance & Accounting, is planning to begin initiatives related to debt and equity within the next six months.
Accounting, Compensation & Benefits, Employee Relations, Workforce Management, Financial Reporting, Business Finance, Finance, Financing & Debt
Project
Accounting, Enterprise Software, Software, Financial Reporting, Enterprise Resource Planning, Finance
Xynomic Pharmaceuticals News & Media
Xynomic Pharma Receives Fast-Track Designation from the US FDA for Abexinostat as 4L Therapy Treating Follicular Lymphoma
SHANGHAI, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast-Track designation to Xynomic’s lead drug candidate abexinostat, for use as a single agent, as a fourth-line treatment of relapsed or refractory follicular lymphoma (“FL”). Fast-Track is a designation by the FDA to facilitate the developmeXynomic Pharma Doses First Chinese Patient in Pivotal Phase 3 Kidney Cancer Trial and Hires Medical Monitor
SHANGHAI, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, today announced the dosing of the first Chinese patient in its on-going global pivotal Phase 3 trial of Xynomic’s abexinostat combined with pazopanib as a first- or second-line therapy against renal cell carcinoma (RCC) at Peking University Cancer Hospital & Institute. Dr. Jun Guo, Professor and Medical DirectoXynomic Pharma Reports Encouraging Interim Data from Phase 1b Study of Abexinostat Combined with Keytruda® in Multiple Solid Tumors
RALEIGH, N.C. and SHANGHAI, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, announced encouraging interim data from an ongoing Phase 1b study of its lead candidate abexinostat, an orally dosed, hydroxamic acid-based small molecule histone deacetylase (“HDAC”) inhibitor , in combination with Keytruda®, for the treatment of multiple solid tumors. The trial is being conductedXynomic Research Institute Has Successfully Designed a Series of Potent RET Kinase Inhibitors
RALEIGH, N.C. and SHANGHAI, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, stock ticker: XYNO), a clinical stage US-China oncology drug development company, announced that Xynomic Research Institute (“XRI”) has successfully designed a series of potent RET kinase inhibitors by computer-assisted drug design. Rearranged during transfection (“RET”) is a receptor tyrosine kinase that activates multiple downstream pathways involved in cell proliferation and surviv
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Xynomic Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage biopharmaceutical company specializing in best-in-class oncology therapeutics. The company focuses on in-licensing, developing, and commercializing oncology drug candidates in China, the US, and globally. Their target clients include healthcare providers and patients in need of innovative c... Read More
